[{"id":"9a8bbdf2-e4b9-4ba0-a574-823381bdf9e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05610891","created_at":"2022-11-09T13:56:43.468Z","updated_at":"2024-07-02T16:35:03.279Z","phase":"Phase 1","brief_title":"Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG","source_id_and_acronym":"NCT05610891","lead_sponsor":"Cellectar Biosciences, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e iopofosine I-131 (CLR 131)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-05-16"},{"id":"ac955a6c-ca84-4da0-949d-41199f5759b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03478462","created_at":"2021-01-18T17:08:27.106Z","updated_at":"2024-07-02T16:35:47.764Z","phase":"Phase 1","brief_title":"Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma","source_id_and_acronym":"NCT03478462","lead_sponsor":"Cellectar Biosciences, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e iopofosine I-131 (CLR 131)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/30/2019","start_date":" 04/30/2019","primary_txt":" Primary completion: 09/25/2022","primary_completion_date":" 09/25/2022","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-05-17"}]